Estrogen Receptor Antagonists

Estrogen Receptor Antagonist

P-Glycoprotein Inhibitors

Breast Cancer Resistance Protein Inhibitors

Breast Neoplasms

<section class="Section" data-sectioncode="34089-3"><a name="s_1100"></a><a name="section-9"></a><h1>11 DESCRIPTION</h1>Elacestrant hydrochloride is the salt form of elacestrant, an estrogen receptor antagonist, that has the chemical name: (6R)-6-(2-(N-(4-(2-(ethylamino)ethyl)benzyl)-N-ethylamino)-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol dihydrochloride. Elacestrant hydrochloride is the dihydrochloride salt and the molecular formula is C30H38N2O2.2HCL. The relative molecular mass is 531.56 g/mol. The chemical structure of elacestrant hydrochloride is shown below: <img alt="Chemical Structure" src="elacestrant-01.jpg"/>Elacestrant hydrochloride is a white to off-white to grey solid and is freely soluble in 0.01N HCI. ORSERDU (elacestrant) 345 mg film-coated tablet contains 400 mg of elacestrant hydrochloride (approximately 345 mg of elacestrant free base).ORSERDU (elacestrant) 86 mg film-coated tablet contains 100 mg of elacestrant hydrochloride (approximately 86 mg of elacestrant free base).Both tablet strengths contain the following inactive ingredients: colloidal silicon dioxide, crospovidone, magnesium stearate (non-bovine), microcrystalline cellulose, and silicified microcrystalline cellulose. The tablets also contain Opadry II Blue (polyvinyl alcohol, titanium dioxide, polyethylene glycol, FD&amp;C Blue #1 and talc).</section>

ORSERDU

elacestrant

elacestrant 86 MG Oral Tablet

Orserdu

elacestrant 86 MG Oral Tablet [Orserdu]

elacestrant 345 MG Oral Tablet

elacestrant 345 MG Oral Tablet [Orserdu]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information

Medication Guide 

Pharmacy List 

How To Order Orserdu

Orserdu Enrollment Form 

Coverage Authorization Request 

Coverage Authorization Appeals

Letter of Medical Necessity 

Orserdu Access and Reimbursement Guide 

Enroll in Patient Savings Program 

About Orserdu 

Taking Orserdu 

Side Effects 

Patient Resources 

Patient Brochure

Stemline ARC Support 

Instructions For Use: Metastatic Breast Cancer (ER+ HER- ESR1-Mutated)

Patient Stories

Understanding ESR1 Mutation